Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Groundbreaking research to evaluate the effects of EL-32, alone and in combination with semaglutide, on glycemic control and body composition in diet-induced obese mice.EL-32 is an engineered probiotic expressing dual myostatin & activin-A, focusing on two clinically validated targets that play an important role in regulating muscle. NEWPORT BEACH, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (NASDAQ:ELAB), today announced that its subsid ...